Plasmapheresis and lipid-lowering therapy in patients with chronic renal failure

Zhdanova T. V., Usankin I. S., Borzunova N. S.,

Nazarov A. V., Plaksina S. S., Borzunov I. V.

SBEI HPE USMU Russian Ministry of Health
State budget educational institution higher education
«Ural State Medical University»
Ministry of Health of the Russian Federation, Ekaterinburg;
Municipal autonomous institution City Clinical Hospital № 40, Ekaterinburg, Russian Federation

Abstract.
This article presents the current scientific data on the pathophysiological mechanisms of atherogenesis and progression of renal damage in patients with dyslipidemia at different stages of CKD. Methods are described for medical correction levels of atherogenic lipoproteins in patients with CKD. Further, use of world experience shows various extracorporeal elimination lipoproteins compare their performance to the effects of these treatments for the underlying disease, as well as the results of studies on their safety.

Key words:
dyslipidemia, chronic kidney disease, hemodialysis, apheresis LDL, double filtration plasmapheresis

REFERENCES
1. Segura J, Garcia-Donair J, Praga M, et al. Chronic kidney disease as a situation of high added risk in hypertensive patients. J Am Soc Nephrol 2006; 17 (Suppl 2.): 136-40
2. Smirnov AV, Dobronravov VA, Kayukov IG — «Cardio-renal continuum: pathogenetic basis of the modern nephrology». Nephrology 2005 is 9. No. 3. pp. 2-15
3. El Husseini N, Kaskar O, Goldstein LB. «Chronic kidney disease and stroke». Adv Chronic Kidney Dis. 2014; 21 (6): 500-8
4. Horl WH Platelet dysfunction in Uremia. Wien Klin Wochenschr. 2006; 118 (5-6): 134-50.
5. Osikov MV, Grigoriev TA Pathochemical patterns of platelet dysfunction in patients with chronic renal failure on hemodialysis. Bulletin of the South Ural State University, No. 26 (243) / 2011: pp. 79-82.
6. Zhdanovа TV, Borzunova NS, Nazarov AV — Features of lipid metabolism in patients with CKD and the effect of lipid-lowering drugs on renal hemodynamics. atherosclerosis and dyslipidemia, 2014 that No. 4 (17) pp. 5-13.
7. Bhowmik D., Tiwari S.C. Metabolic syndrome and chronic kidney disease. Indian J Nephrol. 2008; 18 (1): 1-4.
8. Kuznetsova EV, Zhdanovа TV, Sadykova YR et al. Metabolic syndrome in nephrology patients. Urals medical journal. 2011; 4: 34-41.
9. MS Safarova, Afanasyev OI Application apheresis lipoproteins in atherosclerosis and its complications. «Atherosclerosis and dyslipidemia,» 2014 No. 2 (15): 5-16.
10. Zhdanovа TV, Mazur VI, Nazarov AV et al. Pathogenetic aspects of atherosclerosis in patients with chronic renal failure. Nizhny Novgorod Medical Journal. 2004; 4: 146-151.
11. Keane W.F. Lipids and the kidney. Kidney international. 1994; 46 (3): 910 920.
12. Gröne E.F., Gröne H.J. Does hyperlipidemia injure the kidney? Nature clinical practice. Nephrology .2008; 4 (8): 424-425.
13. Urazlina SE, Zhdanov TV, AV Nazarov et al. Lipid metabolism in patients with chronic renal failure. Urals medical journal. 2011; 2 (80): 122-126.
14. Tareeva IE, Kutyrina IM, Nikolaev AY The braking of chronic renal failure // Therapeutic archive. 2000; 6: 9-14.
15. Thompson G.R, Barbir M, Davies D, et al. Recommendations for the use of LDL apheresis. Atherosclerosis. 2008; 198: 247-55.
16. Song H.M., Wei M, Xu K, Li XW. Differential effect of three mitogen-activated protein kinases on lipoprotein (a) -induced human mesangial cell proliferation. Chin Med J (Engl). 2010 Jan 20; 123 (2): 216-20.
17. Muso E, Mune M, Hirano T, Hattori M, Kimura K, Watanabe T, Yokoyama H, Sato H, Uchida S, Wada T, Shoji T, Yuzawa Y, Takemura T, Sugiyama S, Nishizawa Y, Ogahara S, Yorioka N, Sakai S, Ogura Y, Yukawa S, Iino Y, Imai E, Matsuo S, Saito T. Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study. Clin Exp Nephrol. 2014 Jun 17.
18. Attman PO, Alaupovic P., Tavella M. and Knight-Gibson C. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure. Nephrol Dial Transplant (1996) 11: 63-69.
19. Colinа IB Influence of lipid disorders on the course and prognosis of chronic glomerulonephritis with nephrotic syndrome. Ph.D. diss M., 2002.
20. National Kidney Foundation. K. DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39 (Suppl 1): Sl-266.
21. Tonelli M, Wanner C; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. Ann Intern Med. 2014; 4; 160 (3).
22. Morita T, Morimoto S, Nakano C, Kubo R, Okuno Y, Seo M, Someya K, Nakahigashi M, Ueda H, Toyoda N, Kusabe M, Jo F, Takahashi N, Iwasaka T, Shiojima I. Renal and vascular protective effects of ezetimibe in chronic kidney disease. Intern Med. 2014; 53 (4): 307-14.
23. Ishimitsu T, Ohno E, Ueno Y, Onoda S, Nagase A, Ohira T, Nakano N, Satonaka H. Effects of atorvastatin and ezetimibe on endothelial function in dyslipidemic patients with chronic kidney disease. Clin Exp Nephrol. 7, 2013
24. Efferent therapy. edited by Kostyuchenko AL — St. Petersburg M.: IKF «Tome». — 2003. – 432 p.
25. Kaplan A.A. Therapeutic plasma exchange: core curriculum 2008. Am J Kidney Dis 2008; 52: 1180.
26. Schettler V, Neumann CL, Hulpke-Wette M, et al. The German Apheresis Working Group. Current view: indications for extracorporeal lipid apheresis treatment. Clin Res Cardiol Suppl. 2012; 7 (Suppl 1): 15-19.
27. EA Stetsyuk «Fundamentals of hemodialysis», Moscow, ID «GEOTAR-Med», 2001, 319-338.
28. Abrahamyan MV «Opportunities lipafereza in treatment of atherosclerosis». Creative cardiology. 2007; 1-2: 208-219.
29. Sato E, Amaha M, Nomura M, Matsumura D, Ueda Y, Nakamura T. LDL-apheresis contributes to survival extension and renal function maintenance of severe diabetic nephropathy patients: A retrospective analysis. Diabetes Res Clin Pract. 2014; 106 (2): 241-6.
30. Nakamura T, Kawagoe Y, Ogawa H, Ueda Y, Hara M, Shimada N, Ebihara I, Koide H. Effect of low-density lipoprotein apheresis on urinary protein and podocyte excretion in patients with nephrotic syndrome due to diabetic nephropathy. Am J Kidney Dis. 2005; 45 (1): 48-53.
31. Demetriou K, H'Maltezou E, Pierides AM Familial homozygous hypercholesterolemia: effective long-term treatment with cascade double filtrationplasmapheresis. Blood Purif. 2001; 19 (3): 308-13.
32. Bambauer R, Schiel R, Latza R. Current topics on low-density lipoprotein apheresis. Ther Apher. 2001; 5 (4): 293-300.
33. Bhowmik D, Jain PK, Masih JA et al. Tandem plasmapheresis and hemodialysis. Ther Apher 2001; 5: 439-44.
34. Candrina R, Spandrio S, Cotelli MC, Rossi M, Di Stefano O Double filtration plasmapheresis in the treatment of vascular complications of hyperlipidemia. Recenti Prog Med. 1990; 81 (4): 282-6.
35. Bambauer R, Schiel R, Latza R. «Low-density lipoprotein apheresis: an overview» // Ther Apher Dial. 2003; 7 (4): 382-90.
36. Kawasaki Y, Suzuki S, Matsumoto A, Takano K, Suyama K, Hashimoto K, Suzuki J, Suzuki H, Hosoya M. Long-term efficacy of low-density lipoprotein apheresis for focal and segmental glomerulosclerosis. Pediatr Nephrol. 2007; 22 (6): 889-92.
37. Oto J, Suga K, Matsuura S, Kondo S, Ohnishi Y, Inui D, Imanaka H, Kagami S, Nishimura M. Low-density lipoprotein apheresis in a pediatric patient with refractory nephrotic syndrome due to focal segmental glomerulosclerosis. J Anesth. 2009; 23 (2): 284-7.
38. Hattori M, Chikamoto H, Akioka Y, Nakakura H, Ogino D, Matsunaga A, Fukazawa A, Miyakawa S, Khono M, Kawaguchi H, Ito KA combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis. 2003; 42 (6): 1121-30.
39. Kobayashi T, Ando Y, Umino T, Miyata Y, Muto S, Hironaka M, Asano Y, Kusano E. Complete remission of minimal-change nephrotic syndrome induced by apheresis monotherapy. Clin Nephrol. 2006; 65 (6): 423-6.
40. Shiraishi N, Kitamura K, Hayata M, Ogata T, Tajiri-Okamura K, Nakayama Y, Kohda Y, Tomita K, Mukoyama M. Low-Density Lipoprotein Apheresis for Proteinuria in Lupus Nephritis With Intraglomerular Foam Cells Containing Cholesterol Crystals. Am J Kidney Dis, 2014
41. Jansen M1, Gabriel H, Banyai S, Pidlich J, Weidinger F, Hörl WH, Derfler K. Regression of coronary atherosclerosis and amelioration of renal function during LDL-immunoadsorption therapy in a renal transplant recipient. Wien Klin Wochenschr. 1996; 108 (14): 425-31.
42. Tsurumi-Ikeya Y, Tamura K, Azuma K, Mitsuhashi H, Wakui H, Nakazawa I, Sugano T, Mochida Y, Ebina T, Hirawa N, Toya Y, Uchino K, Umemura S. Sustained inhibition of oxidized low-density lipoprotein is involved in the long-term therapeutic effects of apheresis in dialysis patients. Arterioscler Thromb Vasc Biol. 2010; 30 (5): 1058-65
43. Iwagami M, Mochida Y, Ishioka K, Oka M, Moriya H, Ohtake T, Hidaka S, Kobayashi S. LDL-apheresis dramatically improves generalized calciphylaxis in a patient undergoing hemodialysis. Clin Nephrol. 2014; 81 (3): 198-202.
44. Tamura K, Tsurumi-Ikeya Y, Wakui H, Maeda A, Ohsawa M, Azushima K, Kanaoka T, Uneda K, Haku S, Azuma K, Mitsuhashi H, Tamura N, Toya Y, Tokita Y, Kokuho T, Umemura S. Therapeutic potential of low-density lipoprotein apheresis in the management of peripheral artery disease in patients with chronic kidney disease. Ther Apher Dial. 2013; 17 (2): 185-92.
45. Morimoto S, Yano Y, Maki K, Sawada K, Iwasaka T. Efficacy of low-density lipoprotein apheresis in patients with peripheral arterial occlusive disease undergoing hemodialysis treatment. Am J Nephrol. 2007; 27 (6): 643-8.
46. Nakajima F, Morimoto S, Yurugi T, Amari Y, Kasuno Y, Fukui M, Furumatsu Y, Kitamura T. Increment of cerebral blood flow by LDL-apheresis in dialysis patients with arteriosclerosis obliterans: a pilot study. Int J Artif Organs. 2012; 35 (11): 981-5.
47. Russi G, Furci L, Leonelli M, Magistroni R, Romano N, Rivasi P, Albertazzi A. Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced Extracorporeal Lipoprotein Precipitation system): a case report. J Med Case Rep. 2009 2; 3: 9311.
48. Eisenhauer T, Müller U, Schuff-Werner P, Armstrong VW, Bosch T, Thiery J, Gurland H, Seidel D Simultaneous heparin extracorporeal LDL precipitation and hemodialysis. First clinical experience. ASAIO Trans. 1991; 37 (3): M494-6
49. Bramlage CP, Armstrong VW, Zapf A, Bramlage P, Mueller GA, Koziolek MJ. Low-density lipoprotein apheresis decreases ferritin, transferrin and vitamin B12, which may cause anemia in serially treated patients. Ther Apher Dial. 2010; 14 (2): 136-42.

Authors
Zhdanovа Tatiana V. 
Professor, MD, Head of the Department of Internal Medicine Propaedeutics

Usankin Ilya S. 
intern of the Department of Internal Medicine Propaedeutics

Borzunova Natalia S. 
graduate student of the Department of Internal Medicine Propaedeutics

Plaksina Snezhana S. 
4th year student OLD

Borzunov Igor V. 
MD, professor of urology
State Educational Institution of Higher Professional Education Ural State Medical University, Ministry of Health of the Russian Federation Ministry of Health Medical University (UGMU Russia)
620109, Russian Federation, Ekaterinburg, Repinа, 3

Nazarov Andrew V. 
Professor, MD, head of the dialysis
Municipal Autonomous Institution Clinical Hospital № 40 Ekaterinburg
Russian Federation, Ekaterinburg, Volgogradskaya, 189